Results posted for onapristone-anastrozole trial in refractory endometrial cancer
Thomas Jefferson University's phase 2 study testing onapristone plus anastrozole in refractory hormone receptor positive endometrial cancer, with Context Therapeutics as collaborator, posted results after completion.
Results for a small phase 2 study of an onapristone and anastrozole combination were posted this week.
- **Onapristone plus anastrozole, phase 2, refractory HR-positive endometrial cancer**: This trial is sponsored by Thomas Jefferson University, with Context Therapeutics Inc. listed as a collaborator1. The study status is completed, with a start date of January 28, 2021, primary completion on March 1, 2025, and study completion on December 17, 20251. Results were first posted on July 17, 20261. The trial evaluated the pure progesterone receptor antagonist extended-release onapristone combined with anastrozole in women with recurrent metastatic ER-positive/PR-positive endometrial carcinoma1, enrolling 14 participants1 across several refractory endometrial cancer subtypes. The primary outcome was objective response rate, defined as the percentage of patients with complete or partial tumor response per RECIST 1.1 criteria1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.